Viridian Therapeutics (STU:1S1) Cyclically Adjusted FCF per Share: €-16.97 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S1 Viridian Therapeutics Inc STU:1S1
52 GF Score
Price €19.90
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Cyclically Adjusted FCF per Share?

Viridian Therapeutics STU:1S1 -1.49% 52 Cyclically Adjusted FCF per Share is €-16.97 as of Jun. 2026. GuruFocus rates STU:1S1 with a GF Score™ of 52/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Viridian Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.858. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-16.97 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 31.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Viridian Therapeutics was 31.60% per year. The lowest was 31.60% per year. And the median was 31.60% per year.

As of today (2026-08-11), Viridian Therapeutics's current stock price is €19.90. Viridian Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-16.97. Viridian Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Viridian Therapeutics  (STU:1S1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Viridian Therapeutics Cyclically Adjusted FCF per Share Related Terms


Viridian Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Cyclically Adjusted FCF per Share Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -86.35 -79.41 -53.29 -25.89

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.81 -28.93 -25.89 -21.37 -16.97

STU:1S1 vs BHVN, AGIO, SION: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Viridian Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:1S1
52GF Score
Viridian Therapeutics Inc STU:1S1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viridian Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.858/333.9520*333.9520
=-0.858

Current CPI (Jun. 2026) = 333.9520.

Viridian Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -20.854 241.428 -28.846
201612 -36.306 241.432 -50.219
201703 -9.990 243.801 -13.684
201706 -4.479 244.955 -6.106
201709 -3.341 246.819 -4.520
201712 -4.130 246.524 -5.595
201803 -3.424 249.554 -4.582
201806 -1.949 251.989 -2.583
201809 -2.932 252.439 -3.879
201812 -3.515 251.233 -4.672
201903 -5.092 254.202 -6.689
201906 -3.087 256.143 -4.025
201909 -4.068 256.759 -5.291
201912 -3.254 256.974 -4.229
202003 -2.525 258.115 -3.267
202006 -1.704 257.797 -2.207
202009 -1.163 260.280 -1.492
202012 -1.971 260.474 -2.527
202103 -1.532 264.877 -1.932
202106 -1.504 271.696 -1.849
202109 -0.917 274.310 -1.116
202112 -0.615 278.802 -0.737
202203 -0.738 287.504 -0.857
202206 -0.626 296.311 -0.706
202209 -0.622 296.808 -0.700
202212 -0.796 296.797 -0.896
202303 -1.373 301.836 -1.519
202306 -0.972 305.109 -1.064
202309 -0.845 307.789 -0.917
202312 -0.700 306.746 -0.762
202403 -0.681 312.332 -0.728
202406 -0.670 314.175 -0.712
202409 -0.918 315.301 -0.972
202412 -0.874 315.605 -0.925
202503 -1.055 319.799 -1.102
202506 -0.801 322.561 -0.829
202509 -0.883 324.800 -0.908
202512 -0.217 324.054 -0.224
202603 -1.013 330.213 -1.024
202606 -0.858 333.952 -0.858

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-16.97 mean?
Viridian Therapeutics (STU:1S1) has a Cyclically Adjusted FCF per Share of €-16.97 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Viridian Therapeutics and its competitors.
Is Viridian Therapeutics' Cyclically Adjusted FCF per Share too high?
Viridian Therapeutics' current Cyclically Adjusted FCF per Share is €-16.97. Overall, Viridian Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Cyclically Adjusted FCF per Share compare to BHVN and AGIO?
Viridian Therapeutics' Cyclically Adjusted FCF per Share of €-16.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current Cyclically Adjusted FCF per Share is €-16.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (STU:1S1) has a current Cyclically Adjusted FCF per Share of €-16.97. The current Cyclically Adjusted FCF per Share is €-16.97. Viridian Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current Cyclically Adjusted FCF per Share is €-16.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA0K1R:UK
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
52GF Score

Get the complete analysis for STU:1S1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.90
Price